Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study

• Published in: Canadian journal of respiratory therapy : CJRT = Revue canadienne de la thérapie respiratoire : RCTR 2024-01, Vol.60, p.86-94
• Main Authors: Pina Belmonte, Adela, Madrazo, Manuel, Piles, Laura, Rubio-Rivas, Manuel, de Jorge Huerta, Lucía, Gómez Antúnez, María, López Caleya, Juan Francisco, Arnalich Fernández, Francisco, Gericó-Aseguinolaza, Martin, Pesqueira Fontan, Paula Maria, Rhyman, Nicolás, Prieto Dehesa, Marina, Romero Cabrera, Juan Luis, García García, Gema María, García-Casasola, Gonzalo, Labirua-Iturburu Ruiz, Ane, Carrasco-Sánchez, Francisco Javier, Martínez Hernández, Sara, Pascual Pérez, Maria de Los Reyes, López Castro, José, Serrano Carrillo de Albornoz, José Luis, Varona, José F, Gómez-Huelgas, Ricardo, Antón-Santos, Juan-Miguel, Lumbreras-Bermejo, Carlos
• Format: Article
• Language: English
• ISSN: 1205-9838; 2368-6820
• DOI: 10.29390/001c.118514

Patients with chronic lung disease (CLD), such as asthma or chronic obstructive pulmonary disease, were expected to have an increased risk of clinical manifestations and severity of COVID-19. However, these comorbidities have been reported less frequently than expected. Chronic treatment with inhaled corticosteroids (ICS) may impact the clinical course of COVID-19. The main objective of this study is to know the influence of chronic treatment with ICS on the prognosis of COVID-19 hospitalized patients with CLD. A multicenter retrospective cohort study was designed, including patients hospitalized with COVID-19. Epidemiological and clinical data were collected at admission and at seven days, and clinical outcomes were collected. Patients with CLD with and without chronic treatment with ICS were compared. Two thousand five hundred ninety-eight patients were included, of which 1,171 patients had a diagnosis of asthma and 1,427 of COPD (53.37% and 41.41% with ICS, respectively). No differences were found in mortality, transfer to ICU, or development of moderate-severe ARDS. Patients with chronic ICS had a longer hospital stay in both asthma and COPD patients (9 vs. 8 days, 0.031 in asthma patients), (11 vs. 9 days, 0.018 in COPD patients); although they also had more comorbidity burden. Patients with chronic inhaled corticosteroids had longer hospital stays and more chronic comorbidities, measured by the Charlson comorbidity index, but they did not have more severe disease at admission, evaluated with qSOFA and PSI scores. Chronic treatment with inhaled corticosteroids had no influence on the prognosis of patients with chronic lung disease and COVID-19.